Financial Data and Key Metrics Changes - Q4 revenue was $59.9 million, up 21.3% year-over-year, with full year revenue increasing 20.2% to $225.2 million [5][18] - Adjusted EBITDA grew 41% to $27.9 million, with a full year adjusted EBITDA margin improving 180 basis points to 12.4% [6][27] - Net loss for Q4 was $13.2 million, or $0.28 per share, compared to a net income of $500,000 or $0.01 per share in Q4 2024 [25] Business Line Data and Key Metrics Changes - Strong growth in all three target markets, with extremities being the most mature market [8] - High double-digit growth in oral maxillofacial and head and neck, driven by surgeon adoption of the AxoGen algorithm [8] - Breast market remains one of the fastest-growing opportunities, with accelerating adoption of Resensation techniques [8] Market Data and Key Metrics Changes - Over 100 procedures completed across 10 clinical sites in the prostate market, with foundational progress made [9] - Approximately 19.8 million additional lives gained coverage in 2025, bringing commercial coverage above 65% [15] - CMS implemented a new outpatient payment classification for nerve procedures, improving the economic profile for outpatient settings [16] Company Strategy and Development Direction - Company aims for a growth target of 15%-20% and plans to continue expanding its commercial organization [4][10] - Focus on achieving standard of care status across core markets and enhancing surgeon education programs [11][12] - Strategic plan includes significant investments in innovation and commercial infrastructure to strengthen financial foundation [29] Management's Comments on Operating Environment and Future Outlook - Management characterized the 2026 revenue growth guidance of at least 18% as prudent, emphasizing the need for careful management of customer creation processes [33] - Confidence in the ability to deliver disciplined growth consistent with long-term strategy, despite the need to prove out quarter to quarter [33] - Anticipation of improved gross margins in 2027 as a result of continuous improvement programs and economies of scale [28][104] Other Important Information - Company completed an upsized public offering, raising $133.3 million in net proceeds, enhancing financial flexibility [7] - FDA approval of the Biologics License Application for Avance marks a significant milestone, establishing it as the standard of reference in nerve repair [14] - Company plans to continue expanding its sales force to achieve full coverage in key markets [50][102] Q&A Session Summary Question: Guidance for the year and assumptions - Management views the 18% guidance as prudent, emphasizing the need for careful management of customer creation processes [33] Question: CMS reimbursement and pricing context - Management noted that while payments have increased, coverage expansion is crucial for future growth [36] Question: Reaction to BLA approval - Positive feedback on product characteristics, with expectations to overcome negative coverage decisions by 2028 [41][44] Question: Sales force additions and productivity - Management indicated that while reaching critical mass, significant growth in sales representatives is still needed to cover the market adequately [49] Question: Gross margin expectations - Management expects gross margin pressure in Q2 due to the introduction of the biologic Avance product, with improvements anticipated in 2027 [55][104] Question: Revenue contribution from prostate market - Prostate market is not expected to be a significant revenue contributor in 2026, pending clinical signals from ongoing studies [83]